Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

Gastroenterology - 1 Sept 2014

Shiovitz Stacey, Bertagnolli Monica M, Renfro Lindsay A, Nam Eunmi, Foster Nathan R, Dzieciatkowski Slavomir, Luo Yanxin, Lao Victoria Valinluck, Monnat Raymond J, Emond Mary J, Maizels Nancy, Niedzwiecki Donna, Goldberg Richard M, Saltz Leonard B, Venook Alan, Warren Robert S, Grady William M

Abstract excerpt

BACKGROUND & AIMS: The CpG island methylator phenotype (CIMP), defined by a high frequency of aberrantly methylated genes, is a characteristic of a subclass of colon tumors with distinct clinical and molecular features. Cohort studies have produced conflicting results on responses of CIMP-positive tumors to chemotherapy. We assessed the association between tumor CIMP status and survival of patients receiving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colectomy

Share to CpG Islands

Share to DNA Mismatch Repair

Share to Fluorouracil

Share to Irinotecan

Share to Leucovorin

Source

Open in PubMed Open full text

Identifiers

PMID: 24859205
DOI: 10.1053/j.gastro.2014.05.009
PMCID: PMC4143495

Genes

BRAF
IGF2
KRAS
NEUROG1
RUNX3
SOCS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.PMID 24859205Read ↗

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.Semantic proximity Read ↗

Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.Semantic proximity Read ↗

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.Semantic proximity Read ↗

The role of the CpG island methylator phenotype on survival outcome in colon cancer.Semantic proximity Read ↗

CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer.Semantic proximity Read ↗

CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.Semantic proximity Read ↗

Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.Semantic proximity Read ↗

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.Semantic proximity Read ↗

No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.Semantic proximity Read ↗

CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.Semantic proximity Read ↗

Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.Semantic proximity Read ↗

Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.